Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sujatha M. Lokanath has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RETRACTED: Lokanath et al. Exploring Chalcone Derivatives as a Multifunctional Therapeutic Agent: Investigating Antioxidant Potential, Acetylcholinesterase Inhibition and Computational Insights. Drugs Drug Candidates 2025, 4, 16

    by Sujatha M. Lokanath, Manjunatha S. Katagi, Girish S. Bolakatti, Johnson Samuel, Belakatte P. Nandeshwarappa

    The journal retracts the article titled “Exploring Chalcone Derivatives as a Multifunctional Therapeutic Agent: Investigating Antioxidant Potential, Acetylcholinesterase Inhibition and Computational Insights”

  • Open Access

    RETRACTED: Exploring Chalcone Derivatives as a Multifunctional Therapeutic Agent: Investigating Antioxidant Potential, Acetylcholinesterase Inhibition and Computational Insights

    by Sujatha M. Lokanath, Manjunatha S. Katagi, Girish S. Bolakatti, Johnson Samuel, Belakatte P. Nandeshwarappa

    Background: The cholinergic hypothesis is an elementary approach employed for the research and drug discovery of novel anti-Alzheimer therapeutics. Method: In this context, the study focuses on synthesizing and evaluating a new series of chalcone derivatives (3a–3j) as multifunctional therapeutic agents, specifically investigating their antioxidant potential using the DPPH method with ascorbic acid as a standard. Ellman’s protocol for acetylcholinesterase inhibition assay was performed using donepezil as a standard, and computational insights were explored through molecular docking and ADME profiling. Results: Compounds 3a, 3d, 3e, 3f, and 3h exhibited excellent antioxidant activity compared to the standard. Most of the compounds exhibited moderate to good (3b, 3c, and 3h) AChE inhibitory activity. Molecular docking studies revealed conventional hydrogen bonding and π-π interactions with the enzyme’s active residues, facilitated by their electronegative groups and phenyl rings, respectively. In addition, a pharmacokinetic study was conducted using computational approach to assess druggability. The results demonstrated that compound 3b is an outstanding lead candidate with appreciable AChE inhibitory activity. Conclusions: The combined experimental and computational results of this study highlight the multifunctional nature of chalcone derivatives, suggesting their potential as promising therapeutic agents for the discovery of novel AChE inhibitors that could be employed in the management of Alzheimer’s disease and oxidative stress-related diseases.


  • Open Access

    Drug Candidates for the Treatment of Alzheimer’s Disease: New Findings from 2021 and 2022

    by Sujatha L. Motebennur, Belakatte P. Nandeshwarappa, Manjunatha S. Katagi

    Alzheimer’s disease (AD), an ongoing neurodegenerative disorder among the elderly, is signalized by amnesia, progressive deficiency in cognitive roles, and behavioral deformity. Over the last ten years, its pathogenesis still remains unclear despite several efforts from various researchers across the globe. There are certain factors that seem to be involved in the progression of the disease such as the accumulation of β-amyloid, oxidative stress, the hyperphosphorylation of tau protein, and a deficit of acetylcholine (ACh). Ongoing therapeutics are mainly based on the cholinergic hypothesis, which suggests that the decrease in the ACh levels leads to the loss of memory. Therefore, increasing the cholinergic function seems to be beneficial. Acetylcholinesterase inhibitors (AChEIs) inhibit the enzyme by avoiding the cleavage of acetylcholine (ACh) and increasing the neurotransmitter acetylcholine (ACh) levels in the brain areas. Thus, the cholinergic deficit is the root cause of Alzheimer’s disease (AD). Currently, drugs such as tacrine, donepezil, rivastigmine, and galantamine have been launched on the market for a cholinergic approach to AD to increase neurotransmission at cholinergic synapses in the brain and to improve cognition. These commercialized medicines only provide supportive care, and there is a loss of medicinal strength over time. Therefore, there is a demand for investigating a novel molecule that overcomes the drawbacks of commercially available drugs. Therefore, butyrylcholinesterase (BChE), amyloid-β (Aβ), β-secretase-1 (BACE), metals Cu(II), Zn(II), or Fe(II), antioxidant properties, and the free radical scavenging capacity have been primarily targeted in the preceding five years along with targeting the AChE enzyme. A desired, well-established pharmacological profile with a number of hybrid molecules incorporating substructures within a single scaffold has been investigated. From distinct chemical categories such as acridine, quinoline, carbamate, huperzine, and other heterocyclic analogs, the main substructures used in developing these molecules are derived. The optimization of activity through structural modifications of the prototype molecules has been followed to develop the Structure Activity Relationship (SAR), which in turn facilitates the development of novel molecules with expected AChE inhibitory activity together with many more pharmacological properties. The present review outlines the current drug candidates in the advancement of these AChEIs in the last two years.